Crestor Safety Defense Misrepresents FDA Position, Agency Tells Company
This article was originally published in The Pink Sheet Daily
Executive Summary
An AstraZeneca “patient safety” print ad that ran in mid-November “misleadingly suggests that the agency does not believe that Crestor poses safety concerns,” the FDA ad division says in an “untitled” letter to the company. The Crestor ad asserted FDA has concluded safety concerns about rosuvastatin “have no medical or scientific basis.”